# Sergio Fazio

List of Publications by Year
in descending order



| 105 | 8,455 | 81839 | 48277 |
|---|---|---|---|
| papers | citations | 39 h-index | 88 g-index |

| 154 | 154 | 154 | 10464 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Macrophage LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) Is Required for the Effect of CD47 Blockade on Efferocytosis and Atherogenesisâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, ATVBAHA121316854. | 1.1 | 12 |
| 2 | Real-world utilization of bempedoic acid in an academic preventive cardiology practice. Journal of Clinical Lipidology, 2022, 16, 94-103. | 0.6 | 16 |
| 3 | Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. Circulation Genomic and Precision Medicine, 2022, 15, 101161CIRCGEN121003503. | 1.6 | 3 |
| 4 | Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. European Journal of Preventive Cardiology, 2021, 28, 816-822. | 0.8 | 21 |
| 5 | Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9. Journal of Lipid Research, 2021, 62, 100003. | 2.0 | 9 |
| 6 | Role of PAI-1 in hepatic steatosis and dyslipidemia. Scientific Reports, 2021, 11, 430. | 1.6 | 50 |
| 7 | Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice. American Journal of Preventive Cardiology, 2021, 5, 100144. | 1.3 | 7 |
| 8 | Divergent low-density lipoprotein receptor (LDLR) linked to low VSV G-dependent viral infectivity and unique serum lipid profile in zebra finches. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 6 |
| 9 | Use of commercial genetic testing to help reclassify LDL receptor variants in clinical practice: A case report. Journal of Clinical Lipidology, 2021, 15, 447-450. | 0.6 | 0 |
| 10 | Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement. American Journal of Preventive Cardiology, 2021, 6, 100183. | 1.3 | 4 |
| 11 | High triglyceride to HDL cholesterol ratio is associated with increased coronary heart disease among White but not Black adults. American Journal of Preventive Cardiology, 2021, 7, 100198. | 1.3 | 8 |
| 12 | Hepatic Sensing Loop Regulates PCSK9ÂSecretion in Response to Inhibitory Antibodies. Journal of the American College of Cardiology, 2021, 78, 1437-1449. | 1.2 | 13 |
| 13 | The PCSK9 revolution: Current status, controversies, and future directions. Trends in Cardiovascular Medicine, 2020, 30, 179-185. | 2.3 | 66 |
| 14 | Preventive cardiology as a dedicated clinical service: The past, the present, and the (Magnificent) future. American Journal of Preventive Cardiology, 2020, 1, 100011. | 1.3 | 9 |
| 15 | Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol. American Journal of Preventive Cardiology, 2020, 1, 100012. | 1.3 | 13 |
| 16 | Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm â€“ 2020 Executive Summary. Endocrine Practice, 2020, 26, 1196-1224. | 1.1 | 117 |
| 17 | Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma. Journal of Clinical Lipidology, 2020, 14, 293-296. | 0.6 | 2 |
| 18 | High-Density Lipoprotein Carries Markers That Track With Recovery From Stroke. Circulation Research, 2020, 127, 1274-1287. | 2.0 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Lipoprotein(a) Gets Worse. Circulation Research, 2020, 126, 1360-1362. | 2.0 | 0 |
| 20 | Subcellular diversion of cholesterol by gainâ€•and lossâ€•ofâ€•function mutations in <scp>PMP22</scp>. Glia, 2020, 68, 2300-2315. | 2.5 | 11 |
| 21 | Lipoprotein(a). JACC Basic To Translational Science, 2020, 5, 558-560. | 1.9 | 1 |
| 22 | The American journal of preventive cardiology: On a mission to help define a specialty. American Journal of Preventive Cardiology, 2020, 1, 100014. | 1.3 | 0 |
| 23 | Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients. JACC: Case Reports, 2020, 2, 396-399. | 0.3 | 12 |
| 24 | Chylomicronemia syndrome: Familial or not?. Journal of Clinical Lipidology, 2020, 14, 201-206. | 0.6 | 21 |
| 25 | Aggressive Treatment for Severe Forms of Familial Hypercholesterolemia. Journal of the American College of Cardiology, 2020, 75, 575-577. | 1.2 | 2 |
| 26 | Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2020, 41, 2313-2330. | 1.0 | 776 |
| 27 | A neutral lipid-enriched diet improves myelination and alleviates peripheral nerve pathology in neuropathic mice. Experimental Neurology, 2019, 321, 113031. | 2.0 | 26 |
| 28 | Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. Journal of the American College of Cardiology, 2019, 74, 1926-1942. | 1.2 | 39 |
| 29 | Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. Circulation Research, 2019, 124, 351-353. | 2.0 | 9 |
| 30 | Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4793-4803. | 1.8 | 12 |
| 31 | Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. Journal of Clinical Lipidology, 2019, 13, 580-585. | 0.6 | 16 |
| 32 | PMP22 Regulates Cholesterol Trafficking and ABCA1-Mediated Cholesterol Efflux. Journal of Neuroscience, 2019, 39, 5404-5418. | 1.7 | 29 |
| 33 | Response by Mueller et al to Letter Regarding Article, â€œDeletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophagesâ€• Circulation, 2019, 139, 1983-1984. | 1.6 | 2 |
| 34 | The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocrine Reviews, 2019, 40, 537-557. | 8.9 | 262 |
| 35 | Application of PCSK9 Inhibitors in Practice. Circulation Research, 2019, 124, 32-37. | 2.0 | 61 |
| 36 | Brief Commentary: Marijuana and Cardiovascular Diseaseâ€”What Should We Tell Patients?. Annals of Internal Medicine, 2019, 170, 119. | 2.0 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139, 1483-1492. | 1.6 | 533 |
| 38 | Medicationâ€based versus targetâ€based lipid management. Journal of Diabetes, 2018, 10, 789-792. | 0.8 | 1 |
| 39 | Biologic bases of residual risk of cardiovascular events: A flawed concept. European Journal of Preventive Cardiology, 2018, 25, 1831-1835. | 0.8 | 8 |
| 40 | CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet. Diabetes, 2018, 67, 2494-2506. | 0.3 | 20 |
| 41 | Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages. Circulation, 2018, 138, 1850-1863. | 1.6 | 71 |
| 42 | Exercise is Associated With Increased Small HDL Particle Concentration and Decreased Vascular Stiffness in Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2018, 24, 417-421. | 0.5 | 11 |
| 43 | Co-occurrence of heterozygous CREB3L3 and APOA5 nonsense variants and polygenic risk in a patient with severe hypertriglyceridemia exacerbated by estrogen administration. Journal of Clinical Lipidology, 2018, 12, 1146-1150. | 0.6 | 4 |
| 44 | The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology, 2018, 72, 314-329. | 1.2 | 162 |
| 45 | Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism. BMC Nephrology, 2018, 19, 17. | 0.8 | 16 |
| 46 | PCSK9. Circulation Research, 2018, 122, 1420-1438. | 2.0 | 198 |
| 47 | Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. Journal of Clinical Lipidology, 2018, 12, 1313-1323. | 0.6 | 66 |
| 48 | â€œTaking a look under the hoodâ€â€”imaging the phenotypic heterogeneity of familial hypercholesterolemia. Journal of Clinical Lipidology, 2018, 12, 1095-1098. | 0.6 | 2 |
| 49 | Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017, 38, 2459-2472. | 1.0 | 2,292 |
| 50 | The PCSK9 adventure â€” humanizing extreme LDL lowering. Nature Reviews Cardiology, 2017, 14, 319-320. | 6.1 | 2 |
| 51 | Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. Journal of Clinical Lipidology, 2017, 11, 667-673. | 0.6 | 40 |
| 52 | A case of severe acquired hypertriglyceridemia in a 7-year-old girl. Journal of Clinical Lipidology, 2017, 11, 1480-1484. | 0.6 | 7 |
| 53 | Setting the Agenda for Preventive Cardiology. Circulation Research, 2017, 121, 211-213. | 2.0 | 15 |
| 54 | Application of PCSK9 Inhibitors in Practice. Circulation Research, 2017, 121, 499-501. | 2.0 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3340-3348. | 1.8 | 29 |
| 56 | PCSK9 and Atherosclerosis - Lipids and Beyond. Journal of Atherosclerosis and Thrombosis, 2017, 24, 462-472. | 0.9 | 59 |
| 57 | Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. F1000Research, 2017, 6, 134. | 0.8 | 63 |
| 58 | Loss of SPRR3 in ApoE-/- mice leads to atheroma vulnerability through Akt dependent and independent effects in VSMCs. PLoS ONE, 2017, 12, e0184620. | 1.1 | 2 |
| 59 | A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 641-653q. | 0.5 | 47 |
| 60 | PCSK9 Association With Lipoprotein(a). Circulation Research, 2016, 119, 29-35. | 2.0 | 99 |
| 61 | Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1122-1131. | 1.1 | 37 |
| 62 | HDL Particle Size and Functional Heterogeneity. Circulation Research, 2016, 119, 704-707. | 2.0 | 19 |
| 63 | Loss of Macrophage Low-Density Lipoprotein Receptorâ€"Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor-Î± Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1483-1495. | 1.1 | 38 |
| 64 | Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Cardiovascular Research, 2016, 112, 429-442. | 1.8 | 105 |
| 65 | Local effects of human <scp>PCSK9</scp> on the atherosclerotic lesion. Journal of Pathology, 2016, 238, 52-62. | 2.1 | 143 |
| 66 | Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovascular Research, 2016, 110, 268-278. | 1.8 | 84 |
| 67 | From Lipids to Inflammation. Circulation Research, 2016, 118, 732-749. | 2.0 | 180 |
| 68 | Macrophage IKKÎ± Deficiency Suppresses Akt Phosphorylation, Reduces Cell Survival, and Decreases Early Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 598-607. | 1.1 | 39 |
| 69 | Isolevuglandin-Type Lipid Aldehydes Induce the Inflammatory Response of Macrophages by Modifying Phosphatidylethanolamines and Activating the Receptor for Advanced Glycation Endproducts. Antioxidants and Redox Signaling, 2015, 22, 1633-1645. | 2.5 | 25 |
| 70 | Macrophage apoAI protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL. Journal of Lipid Research, 2015, 56, 635-643. | 2.0 | 26 |
| 71 | Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. Archives of Medical Research, 2015, 46, 379-391. | 1.5 | 42 |
| 72 | Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism: Clinical and Experimental, 2015, 64, 263-273. | 1.5 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Is it Time to Enhance Assessment of Alcohol Intake in Patients Slated for Statin Therapy?. Current Nutrition Reports, 2015, 4, 1-5. | 2.1 | 2 |
| 74 | Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis. Journal of Lipid Research, 2015, 56, 1449-1460. | 2.0 | 100 |
| 75 | Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Atherosclerosis, 2015, 242, 56-64. | 0.4 | 30 |
| 76 | Response to Letter Regarding Article, â€œProprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptorâ€“Dependent and â€“Independent Mechanismsâ€•. Circulation, 2015, 131, e428. | 1.6 | 0 |
| 77 | Smoking, sex, risk factors and abdominal aortic aneurysms: a prospective study of 18â€…782 persons aged above 65 years in the Southern Community Cohort Study. Journal of Epidemiology and Community Health, 2015, 69, 481-488. | 2.0 | 78 |
| 78 | Sexâ€Specific Parental Effects on Offspring Lipid Levels. Journal of the American Heart Association, 2015, 4, . | 1.6 | 8 |
| 79 | The link between lipids, statins and cancer: is there a role for cardio-oncology?. Future Cardiology, 2015, 11, 389-393. | 0.5 | 1 |
| 80 | On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis, 2015, 238, 264-270. | 0.4 | 70 |
| 81 | PMP22 Is Critical for Actin-Mediated Cellular Functions and for Establishing Lipid Rafts. Journal of Neuroscience, 2014, 34, 16140-16152. | 1.7 | 47 |
| 82 | Identification of Small Proline-Rich Repeat Protein 3 as a Novel Atheroprotective Factor That Promotes Adaptive Akt Signaling in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2527-2536. | 1.1 | 11 |
| 83 | Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice. Journal of Lipid Research, 2014, 55, 2296-2308. | 2.0 | 57 |
| 84 | Response to Duell et al. Circulation Research, 2014, 115, e5. | 2.0 | 0 |
| 85 | The Severe Hypercholesterolemia Phenotype. Journal of the American College of Cardiology, 2014, 63, 1935-1947. | 1.2 | 153 |
| 86 | Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptorâ€“Dependent and â€“Independent Mechanisms. Circulation, 2014, 130, 431-441. | 1.6 | 122 |
| 87 | Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice. Journal of Lipid Research, 2014, 55, 2073-2081. | 2.0 | 8 |
| 88 | Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis. Circulation Research, 2013, 113, 1290-1295. | 2.0 | 73 |
| 89 | A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States. Clinical Epidemiology, 2013, 6, 15. | 1.5 | 22 |
| 90 | PCSK9, a novel target for lowering LDL cholesterol: promise and progress. Clinical Lipidology, 2012, 7, 611-615. | 0.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Evidence-based Management of Lipid Disorders. Clinical Lipidology, 2011, 6, 143-145. | 0.4 | 0 |
| 92 | Low-Density Lipoprotein Receptorâ€“Related Protein 1 Prevents Early Atherosclerosis by Limiting Lesional Apoptosis and Inflammatory Ly-6C‹sup›high‹/sup›Monocytosis. Circulation, 2011, 124, 454-464. | 1.6 | 66 |
| 93 | Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein. Journal of Biological Chemistry, 2011, 286, 43054-43061. | 1.6 | 71 |
| 94 | Macrophage LRP-1 Controls Plaque Cellularity by Regulating Efferocytosis and Akt Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 787-795. | 1.1 | 130 |
| 95 | High-density lipoprotein therapeutics and cardiovascular prevention. Journal of Clinical Lipidology, 2010, 4, 411-419. | 0.6 | 24 |
| 96 | Fenofibrate and risk of minor amputations in diabetes. Lancet, The, 2009, 373, 1740-1741. | 6.3 | 5 |
| 97 | Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity. Biochemistry, 2008, 47, 1631-1639. | 1.2 | 91 |
| 98 | Deletion of Macrophage LDL Receptorâ€“Related Protein Increases Atherogenesis in the Mouse. Circulation Research, 2007, 100, 670-677. | 2.0 | 136 |
| 99 | ACAT1 Deficiency Disrupts Cholesterol Efflux and Alters Cellular Morphology in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 128-134. | 1.1 | 76 |
| 100 | The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy. Current Atherosclerosis Reports, 2004, 6, 148-157. | 2.0 | 106 |
| 101 | Apolipoprotein AI as Therapy for Atherosclerosis: Does the Future of Preventive Cardiology Include Weekly Injections of the HDL Protein?. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2003, 3, 436-440. | 3.4 | 10 |
| 102 | Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. Journal of Lipid Research, 2002, 43, 1602-1609. | 2.0 | 53 |
| 103 | Lack of macrophage fatty-acidâ€“binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nature Medicine, 2001, 7, 699-705. | 15.2 | 616 |
| 104 | Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. Current Atherosclerosis Reports, 2000, 2, 29-35. | 2.0 | 46 |
| 105 | On the Relationship Between Cholesterol Lowering and Coronary Disease Event Rate. Circulation, 1998, 98, 2645-2646. | 1.6 | 5 |